On April 7, 2023, KPMG China's "2nd Biotechnology Innovation Top 50" award ceremony was held simultaneously in Beijing, Shanghai and Shenzhen, and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. was successfully selected.

The selection was based on five key factors: technology and product line leading edge, product pipeline richness and proportion of original products, core management team and R&D team background, capital market activity, and financial health. ImmuneOnco was selected by KPMG China as one of the "2nd Biotech Innovation 50 Companies".

Dr. Wenzhi Tian, Founder and Chairman of ImmuneOnco Biopharmaceuticals, stated:

"We are delighted that ImmuneOnco Biopharmaceuticals has been selected as one of the '2nd Biotech Innovation 50 Companies' by KPMG China, which is a high recognition of ImmuneOnco Biopharmaceuticals’ work in the field of biopharmaceutical innovation and fully reflects the company's strong R&D capability and innovative vigor. The Chinese biotechnology industry has entered an era of great change, and 'innovation' is becoming the theme word for Chinese biotechnology companies. We believe that through the joint efforts of our colleagues in the biopharmaceutical industry, we will be able to make breakthroughs in new drug development in terms of new targets, new mechanisms and new molecules. We also hope to further expand the development advantages of ImmuneOnco Biopharmaceuticals’ anti-tumor immunotherapy products in the future, accelerate clinical trial studies and speed up the pace of product industrialization, so as to benefit cancer patients as soon as possible."